NY-CLOUDREACH
28.1.2021 15:02:31 CET | Business Wire | Press release
Cloudreach , the leading independent multi-cloud services company, today announced the launch of Cloudreach DevOps as a Service. This new offering combines Cloudreach development and operations, making them available ‘as a Service’ via a simple and flexible subscription model. DevOps as a Service is the first of its kind in the market, and fundamentally changes how cloud IT services are consumed to make it easy for enterprises to adopt cloud native technologies and practices.
Dave Chapman, Head of Strategy and Professional Services at Cloudreach, said: “Cloudreach DevOps as a Service brings a DevOps and cloud engineering skill set to any enterprise, whether they are new to the cloud or far along their modernization journey. Companies that undergo cloud transformation are better able to adapt to disruption, explore and innovate faster. This service helps technology leaders get the right skills in place, at the right time, and scale up and down to suit their changing requirements.”
Cloud acceleration
DevOps is a set of practices that combines software development and IT operations, removing the barriers between these traditionally siloed teams. Under a DevOps model, development and operations teams work together across the entire software application life cycle, from development and test through deployment to operations.
More than a decade after the introduction of cloud computing, many enterprises still find themselves suffering from the symptoms of legacy IT and legacy partners. Cloudreach DevOps as a Service makes cloud outsourcing easy by providing flexible engineering squads as a monthly subscription service. The new offering is designed to help technology leaders accelerate their cloud initiatives, embrace true DevOps within their teams, and help their organizations become more cloud native.
Cloudreach DevOps as a Service provides a core DevOps team that can be augmented to perform architecture, platform development, data engineering, application UX and product management roles, all as a unified service. As business priorities or backlogs change, the flexible nature of the service means customers can swap out squad members and scale the team up and down as needed, within a single statement of work. The minimum squad size includes two resources and 80 hours per month, with a minimum contract commitment of three months.
Cloudreach squads have a radical focus on trend improvement and platform evolution. They can help launch new products, accelerate and scale business initiatives, facilitate stronger collaboration with digital teams, or support key applications and infrastructure.
James Dunn, Head of Cloud Platform Development at Cloudreach, said: “Over its 10-year history, Cloudreach has delivered some of the largest and most successful cloud engineering projects in the world. Now we are bringing Cloudreach's cloud native expertise to market in a flexible subscription model.”
- ENDS -
About Cloudreach
Cloudreach is a leading independent cloud services company. Our mission is to deliver the promise of cloud and drive extraordinary value for our customers. Cloudreach helps enterprises win competitive advantage through successful cloud transformation.
With more than 10 years of cloud native experience, we've built an unmatched depth and breadth of expertise in cloud technologies and their application to business. For more information about our services, visit cloudreach.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005535/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom